Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Adial Pharmaceuticals ( (ADIL) ) has shared an announcement.
Adial Pharmaceuticals has announced the scheduling of its 2025 Annual Meeting of Stockholders for July 24, 2025, with a record date set for June 4, 2025. Due to the meeting being scheduled more than 30 days before the anniversary of the previous year’s meeting, the company has revised the deadlines for stockholder proposal submissions. Proposals under Rule 14a-8 must be submitted by May 25, 2025, to be included in the proxy materials, while other proposals or director nominations must also adhere to this deadline.
The most recent analyst rating on (ADIL) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Adial Pharmaceuticals stock, see the ADIL Stock Forecast page.
Spark’s Take on ADIL Stock
According to Spark, TipRanks’ AI Analyst, ADIL is a Underperform.
Adial Pharmaceuticals’ overall stock score is low due to ongoing financial struggles, including a lack of revenue and reliance on external funding. Technical analysis provides no strong directional signal, and valuation metrics are weak due to negative earnings. However, the recent FDA approval for AD04 offers a positive strategic outlook, but this is not enough to counteract the financial and operational challenges currently faced.
To see Spark’s full report on ADIL stock, click here.
More about Adial Pharmaceuticals
Average Trading Volume: 1,321,141
Technical Sentiment Signal: Sell
Current Market Cap: $4.17M
For an in-depth examination of ADIL stock, go to TipRanks’ Stock Analysis page.